|
[1] Chun T W, Fauci A S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS, 2012, 26(10): 1261-1268.
[2] Kent S J, Reece J C, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis, 2013, 13(7): 614-621.
[3] Sgarbanti M, Battistini A. Therapeutics for HIV-1 reactivation from latency. Curr Opin Virol, 2013, 3(4): 394-401.
[4] Deere J D, Schinazi R F, North T W. Simian immunodeficiency virus macaque models of HIV latency. Curr Opin HIV AIDS, 2011, 6(1): 57-61.
[5] Marsden M D, Kovochich M, Suree N, et al. HIV latency in the humanized BLT mouse. J Virol, 2012, 86 (1): 339-347.
[6] Brooks D G, Kitchen S G, Kitchen C M, et al. Generation of HIV latency during thymopoiesis. Nat Med, 2001, 7(4): 459-464.
[7] Cannon P, Kim S H, Ulich C, et al. Analysis of Tat function in human immunodeficiency virus type 1-infected low level-expression cell lines U1 and ACH-2. J Virol, 1994, 68(3): 1993-1997.
[8] Emiliani S, Fischle W, Ott M, et al. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol, 1998, 72(2): 1666-1670.
[9] Emiliani S, Lint C V, Fischle W, et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci USA, 1996, 93(13): 6377-6381.
[10] Barquero A A, Davola M E, Riva D A, et al. Naturally occurring compounds elicit HIV-1 replication in chronically infected promonocytic cells. BioMed Research International, 2014,989101.
[11] Fonteh P, Meyer D. In vitro reactivation of latent HIV-1 by cytostatic bis(thiosemicarbazonate) gold(III) complexes. BMC Infectious Diseases, 2014, 14: 680.
[12] Doyon G, Sobolewski M D, Huber K, et al. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1. PLoS One, 2014, 9(1): e84964.
[13] Sahu G K, Sango K, Selliah N, et al. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly Gp120-positive cells. Virology, 2013, 446:268-275.
[14] Park J, Lim C H, Ham S, et al. Genome-wide analysis of histone modifications in latently HIV-1 infected T cells. AIDS, 2014, 28(12): 1719-1728.
[15] Patel P, Ansari M Y, Bapat S, et al. The microRNA miR-29a is associated with human immunodeficiency virus latency. Retrovirology, 2014, 11(1): 108.
[16] Bhaskar A, Munshi M, Khan S Z, et al. Measuring glutathione redox potential of HIV-1-infected macrophages. J Biol Chem, 2015, 290(2): 1020-1038.
[17] Vemula S V, Veerasamy R, Ragupathy V, et al. HIV-1 induced nuclear factor I-B(NF-IB) expression negatively regulates HIV-1 replication through interaction with the long terminal repeat region. Viruses, 2015, 7(2): 543-558.
[18] Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 2003, 22(8): 1868-1877.
[19] Barton K M, Archin N M, Keedy K S, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One, 2014, 9(8): e102684.
[20] Anderson I, Low J S, Weston S, et al. Heat shock protein 90 controls HIV-1 reactivation from latency. Proc Natl Acad Sci USA, 2014, 111(15): 1528-1537.
[21] Abreu C M, Price S L, Shirk E N, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One, 2014, 9(5): e97257.
[22] Dahabieh M S, Ooms M, Brumme C, et al. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NF-κB. Retrovirology, 2014, 11(1): 17.
[23] Swiggard W J, Bayto P C, Yu J J, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol, 2005, 79(22): 14179-14188.
[24] Saleh S, Solomon A, Wightman F, et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood, 2007, 110(13): 4161-4164.
[25] Margolis D M. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS, 2011, 6 (1): 25-29.
[26] Cameron P U, Saleh S, Sallmann G, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci USA, 2010, 107(39): 16934-16939.
[27] Lassen K G, Hebbeler A M, Bhattacharyya D, et al. A flexible model of HIV-1 latency permitting evaluation of many primary CD4+ T-cell reservoirs. PLoS One, 2012, 7: e30176.
[28] Sahu G K, Lee K, Ji J, et al. A novel in vitro system to generate and study latently HIV infected long-lived normal CD4+ T-lymphocytes. Virology, 2006, 355(2): 127-137.
[29] Marini A, Harper J M, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol, 2008, 181(11): 7713-7720.
[30] Iglesias-Ussel M, Vandergeeten C, Marchionni L, et al. High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol, 2013, 87(16): 9148-9158.
[31] Wang F X, Xu Yan, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest, 2005, 115(1): 128-137.
[32] Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 2009, 113(1): 58-65.
[33] Bosque A, Famiglietti M, Weyrich A S, et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog, 2011, 7: e1002288.
[34] Bonczkowski P, Spiegelaere W D, Bosque A, et al. Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology, 2014, 11: 70.
[35] Mitsuyasu R T. The potential role of interleukin-2 in HIV-1. AIDS, 2001, 15: 22-27.
[36] Mejia E J, Loveridge S T, Stepan G, et al. Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells. J Nat Prod, 2014, 77(3): 618-624.
[37] Wei D G, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4+ T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog, 2014, 10(4): e1004071.
[38] Yang H C, Xing S F, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest, 2009, 119(11): 3473-3486.
[39] Shan L, Xing S F, Yang H C, et al. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother, 2014, 69(1): 28-33.
[40] Shan L, Deng K, Shroff N S, et al. Stimulation of HIV-1 specific cytolytic T-lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity, 2012, 36(3): 491-501.
[41] Planelles V, Wolschendorf F, Kutsch O. Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs. Curr HIV Res, 2011, 9 (8): 568-578.
[42] Tyagi M, Pearson R J, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol, 2010, 84(13): 6425-6437.
[43] Spina C A, Anderson J, Archin N M, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog, 2013, 9: e1003834
[44] Sahu G, Cloyd M. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. J Virol, 2011, 8: 400-406.
|
